Becton Dickinson and Company (BDX)
BDX trades on NYSE in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-09-30, https://www.sec.gov/Archives/edgar/data/10795/000001079525000099/0000010795-25-000099-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-09-30.
Profile
| Field | Value |
|---|---|
| Ticker | BDX on NYSE |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000010795 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | NJ |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $21.8B |
| Net income | $1.7B |
| Operating income | $2.6B |
| Net margin | 7.7% |
| Operating margin | 11.8% |
| Revenue growth | +8.2% |
| Cash | $641.0M |
| Total assets | $55.3B |
| P/E (computed) | 35.1× |
| P/S (computed) | 2.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-06 |
| Cash and burn | $708.0M cash; operating cash flow $1.1B a quarter. | Report 2026-06-30 |
| Shares outstanding | 272,386,800 (2026-06-30); 286,627,469 a year earlier; 290,108,574 three years earlier. 1y figure adjusted for splits (1.272-for-1 overall); 3y figure adjusted for splits (1.272-for-1 overall). | Cover page 2026-06-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2026-06-04 |
| Auditor | Ernst & Young LLP, New York, New York, United States | PCAOB Form AP 2025-12-22 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $2.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-06-30 | $5.0B | $377.0M | $776.0M | $708.0M | $16.8B | $23.3B | 10-Q 2026-08-06 |
| Q2 2026 2026-03-31 | $4.7B | -$311.0M | Not filed | $813.0M | $17.3B | $23.0B | 10-Q 2026-05-07 |
| Q1 2026 2025-12-31 | $5.3B | $382.0M | $657.0M | $740.0M | $19.5B | $22.8B | 10-Q 2026-02-09 |
| Q4 2025 2025-09-30 | $8.3B | $493.0M | $1.9B | $567.0M | $19.2B | $22.7B | 10-K 2025-11-25 |
| Q3 2025 2025-06-30 | $4.7B | $574.0M | $1.1B | $735.0M | $19.3B | $19.8B | 10-Q 2026-08-06 |
| Q2 2025 2025-03-31 | $4.5B | $308.0M | -$204.0M | $667.0M | $19.3B | $20.1B | 10-Q 2026-05-07 |
| Q1 2025 2024-12-31 | $5.2B | $303.0M | $693.0M | $711.0M | $18.8B | $20.6B | 10-Q 2026-02-09 |
| Q4 2024 2024-09-30 | $5.4B | $400.0M | $1.2B | $1.7B | $20.1B | $20.2B | 10-K 2025-11-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2026-05-13 |
| Latest annual report | 10-K | 2025-11-25 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2025-12-18 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.9% |
| 1 month | +16.4% |
| 3 months | +19.8% |
| Year to date | +42.9% |
| 1 year | +43.7% |
| From 52-week high | 0.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BSX | Boston Scientific Corporation | $43.69 | -1.47% | $63.3B |
| MDLN | Medline Inc. | $39.17 | -0.76% | $51.5B |
| MMM | 3M Company | $181.68 | -1.08% | $93.9B |
| RMD | ResMed Inc. | $238.19 | -0.56% | $33.5B |
| DXCM | DexCom Inc. | $81.61 | -2.06% | $30.4B |
| SYK | Stryker Corporation | $310.72 | +0.35% | $118.3B |
| WST | West Pharmaceutical Services Inc. | $417.80 | +0.33% | $29.1B |
| SOLV | Solventum Corporation | $88.65 | -0.48% | $15.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier